CHA Taking Stem Cell-Based Alzheimer’s Therapy Into Clinic
This article was originally published in PharmAsia News
Executive Summary
South Korea's CHA Biotech is set to begin the first clinical trial of a mesenchymal stem cell therapy for Alzheimer's disease, which the company plans to develop on a commercial scale by using proprietary technology that can store the cells for up to 24 months.